TY - JOUR
T1 - Genome-wide identification of inter-individually variable DNA methylation sites improves the efficacy of epigenetic association studies
AU - Hachiya, Tsuyoshi
AU - Furukawa, Ryohei
AU - Shiwa, Yuh
AU - Ohmomo, Hideki
AU - Ono, Kanako
AU - Katsuoka, Fumiki
AU - Nagasaki, Masao
AU - Yasuda, Jun
AU - Fuse, Nobuo
AU - Kinoshita, Kengo
AU - Yamamoto, Masayuki
AU - Tanno, Kozo
AU - Satoh, Mamoru
AU - Endo, Ryujin
AU - Sasaki, Makoto
AU - Sakata, Kiyomi
AU - Kobayashi, Seiichiro
AU - Ogasawara, Kuniaki
AU - Hitomi, Jiro
AU - Sobue, Kenji
AU - Shimizu, Atsushi
N1 - Funding Information:
The authors would like to thank the members of the IMM and the Tohoku Medical Megabank Organisation of Tohoku University (ToMMo) for their encouragement and support. We also acknowledge Dr. Masahiro Nakamura and Dr. Akira Watanabe of Kyoto University, as well as Fuyuki Miya of RIKEN for their useful discussions. We are grateful to the Tohoku Medical Megabank Project participants. This work was supported by the Tohoku Medical Megabank Project (Special Account for Reconstruction from the Great East Japan Earthquake) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) and the Japan Agency for Medical Research and Development (AMED).
Publisher Copyright:
© 2017 The Author(s).
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Epigenome-wide association studies, which searches for blood-based DNA methylation signatures associated with environmental exposures and/or disease susceptibilities, is a promising approach to a better understanding of the molecular aetiology of common diseases. To carry out large-scale epigenome-wide association studies while avoiding false negative detection, an efficient strategy to determine target CpG sites for microarray-based or sequencing-based DNA methylation profiling is essentially needed. Here, we propose and validate a hypothesis that a strategy focusing on CpG sites with high DNA methylation level variability may attain an improved efficacy. Through whole-genome bisulfite sequencing of purified blood cells collected from > 100 apparently healthy subjects, we identified ~2.0 million inter-individually variable CpG sites as potential targets. The efficacy of our strategy was estimated to be 3.7-fold higher than that of the most frequently used strategy. Our catalogue of inter-individually variable CpG sites will accelerate the discovery of clinically relevant DNA methylation biomarkers in future epigenome-wide association studies.
AB - Epigenome-wide association studies, which searches for blood-based DNA methylation signatures associated with environmental exposures and/or disease susceptibilities, is a promising approach to a better understanding of the molecular aetiology of common diseases. To carry out large-scale epigenome-wide association studies while avoiding false negative detection, an efficient strategy to determine target CpG sites for microarray-based or sequencing-based DNA methylation profiling is essentially needed. Here, we propose and validate a hypothesis that a strategy focusing on CpG sites with high DNA methylation level variability may attain an improved efficacy. Through whole-genome bisulfite sequencing of purified blood cells collected from > 100 apparently healthy subjects, we identified ~2.0 million inter-individually variable CpG sites as potential targets. The efficacy of our strategy was estimated to be 3.7-fold higher than that of the most frequently used strategy. Our catalogue of inter-individually variable CpG sites will accelerate the discovery of clinically relevant DNA methylation biomarkers in future epigenome-wide association studies.
UR - http://www.scopus.com/inward/record.url?scp=85034851310&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85034851310&partnerID=8YFLogxK
U2 - 10.1038/s41525-017-0016-5
DO - 10.1038/s41525-017-0016-5
M3 - Article
AN - SCOPUS:85034851310
SN - 2056-7944
VL - 2
JO - npj Genomic Medicine
JF - npj Genomic Medicine
IS - 1
M1 - 0016
ER -